Posts

Vysnova Awarded IDIQ Contract For FC3 AM&E Under DSCA
,

Vysnova Awarded IDIQ Contract For FC3 AM&E Under DSCA

Vysnova Awarded IDIQ Contract For FC3 AM&E Under DSCA

Vysnova Awarded IDIQ Contract For FC3 AM&E Under DSCA

September 30, 2019:  Vysnova Partners Inc. (Vysnova) has been awarded an indefinite-delivery/indefinite-quantity (IDIQ) contract for Functional Category 3 (FC 3) under the Defense Security Cooperation Agency (DSCA) Assessment, Monitoring, and Evaluation (AM&E) support services for the next five years. The FC 3 AM&E provides AM&E evaluations including designing and conducting evaluations of the efficiency and effectiveness of security cooperation planning, programs and activities in achieving desired outcomes. Vysnova is one of five (5) companies participating in the FC 3 IDIQ contract, which has a maximum value of $150,000,000.
 
Vysnova, and our team member, DevTech Systems are considered experts in providing innovative monitoring and evaluating services as part of complex multi-sectoral programs. Our experts ensure that programs address accountability, measure impact, and use best practices and tools to improve program effectiveness. We look forward to supporting DSCA in their critical mission.
Vysnova Awarded TO 0709 Under NAMRU-2 SABER II IDIQ Contract
,

Vysnova Awarded TO 0709 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Awarded TO 0709 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Awarded TO 0709 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0709 (TO 0709) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0709 Vysnova will conduct active surveillance for high pathogenic and lethal strains of influenza A (H7N9) in high risk regions of Vietnam.

vysnova-saberII-Contract
,

Vysnova Awarded TO-0734 Under NAMRU 2 SABER II IDIQ Contract

 

Vysnova Awarded TO-0734 Under NAMRU 2 SABER II IDIQ Contract

 

September 30, 2018: Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0734 (TO 0734) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0734 Vysnova will develop a Viet Nam malaria country plan. Specifically, TO 0734 will involve conducting interviews with malaria control personnel and agencies within Viet Nam to identify gaps in current programs as well as providing recommendations for training, material and research to address gaps.

Vysnova Partners Inc. Awarded TO 0740 Under NAMRU-2 SABER II IDIQ Contract
,

Vysnova Partners Inc. Awarded TO 0740 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0740 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0740 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0740 (TO 0740) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0740 Vysnova will provide support to conduct a surveillance research study for dengue and dengue-like illnesses that present to the Johor Bahru District Health Office’s fever clinic in Malaysia.

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract
, ,

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0738 (TO 0738) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0738 Vysnova will provide an in-depth analysis for a clinical study evaluating the role of the candidate predictive biomarker, tryptase, for dengue fever security.